Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 9/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826225 | 0.88 | KIF11 (0.45) | KIF11ESR1ESR2ARHSD11B1 | |
| SCHEMBL20811730 | 0.86 | DAO (0.40) | KIF11ESR1ESR2ARTAS1R3 | |
| SCHEMBL10268650 | 0.86 | KIF11 (0.46) | KIF11ESR1ESR2S1PR1DAO | |
| SCHEMBL29335336 | 0.83 | KIF11 (0.47) | KIF11ESR1ESR2AR | |
| SCHEMBL14041015 | 0.81 | PTPN5 (0.42) | KIF11TAS1R3TAS1R1 | |
| SCHEMBL18899605 | 0.80 | ESR1 (0.46) | KIF11ESR1ESR2ARKLF10 | |
| SCHEMBL15746150 | 0.79 | KIF11 (0.42) | KIF11ESR1ESR2ARHSD11B1 | |
| SCHEMBL14748164 | 0.78 | ALDH1A1 (0.40) | KIF11ESR1ESR2AR | |
| SCHEMBL11932055 | 0.77 | ESR1 (0.38) | KIF11ESR1ESR2TAS1R3TAS1R1 | |
| SCHEMBL11932057 | 0.76 | ALDH1A1 (0.38) | KIF11ESR1ESR2ARTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | KIF11 1881/4885ESR1 3981/4885ESR2 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.